Bisphosphonates Current Events

Bisphosphonates Current Events, Bisphosphonates News Articles.
Sort By: Most Viewed | Most Recent
Page 1 of 6 | 208 Results
Study sheds light on atypical periprosthetic femoral fractures
Following surgery, some patients experience a broken bone around the implants of a total hip replacement--called a periprosthetic femoral fracture. (2018-10-03)

Bone loss drugs may help prevent endometrial cancer
A new analysis suggests that women who use bisphosphonates -- medications commonly used to treat osteoporosis and other bone conditions -- have about half the risk of developing endometrial cancer as women who do not use the drugs. (2014-12-22)

Study provides insights on optimal treatment of Paget's disease of bone
In a study of patients with Paget's disease of bone--a common skeletal disorder that can lead to bone deformity, fractures, osteoarthritis, and bone pain -- long-term intensive bisphosphonate therapy conferred no clinical benefit over giving bisphosphonates only when patients felt bone pain. (2017-02-08)

Common bone drug may extend life of replacement joints
People who take bisphosphonates after joint replacement surgery are less likely to need a repeat operation, finds a new study published on today. (2011-12-06)

Osteoporosis drugs may increase risk of serious eye disease
Drugs that are commonly used to prevent osteoporosis may increase the risk of serious inflammatory eye disease in first-time users, found an article in CMAJ. (2012-04-02)

Bone drug may be beneficial for knee osteoarthritis
Bisphosphonates (a class of drugs that prevent the loss of bone density and used to treat osteoporosis and similar diseases) appear to be safe and beneficial for osteoarthritis patients. (2020-08-05)

Use of osteoporosis drugs have dropped following media reports of safety concerns
Following a decade of steady growth, use of bisphosphonates -- medications that are effective for treating osteoporosis -- declined in the United States by more than 50 percent from 2008 to 2012. (2015-06-15)

Task force provides guidance on use of osteoporosis drugs
A new report by a task force of the American Society for Bone and Mineral Research provides guidance on the use of bisphosphonates, which are the most commonly used medications for osteoporosis. (2016-01-19)

Long term use of oral bisphosphonates may double risk of esophageal cancer
People who take oral bisphosphonates for bone disease over five years may be doubling their risk of developing esophageal cancer (cancer of the gullet), according to a new study published on today. (2010-09-02)

Experts question whether preventive drugs are value for money
Experts today challenge the view that popular drugs to prevent disease -- like statins and anti-hypertensives to prevent heart disease and stroke, or bisphosphonates to prevent fractures -- represent value for money. (2011-04-19)

Osteoporosis drugs increase risk for heart problems
New research, presented at CHEST 2008 shows that people taking alendronate or zoledronic acid, two common medications to prevent or slow the occurrence of osteoporosis, were significantly more likely to experience serious atrial fibrillation, including hospitalization or death, compared with placebo. (2008-10-27)

Oral osteoporosis meds appear to reduce the risk of jaw degradation
Contrary to recent reports, oral osteoporosis medications that inhibit bone breakdown reduce the risk of jaw problems, based on an analysis of medical claims. Some doctors and dentists had advised patients who take oral osteoporosis medications such as Fosamax and Boniva to postpone dental work, fearing that tooth extractions and other procedures would exacerbate jaw problems purportedly linked to the medication. But the new findings refute the link and suggest the benefits of dentistry likely outweigh the risks for many of these patients. (2008-01-02)

X-rays help predict permanent bone damage from bisphosphonates
Bisphosphonates have been found to place people at risk for developing osteonecrosis of the jaws (a rotting of the jaw bones). Dentists, as well as oncologists, are now using X-rays to detect (2009-05-07)

Serious oral post-surgical complication identified in patient on prescribed therapy for osteopenia
The patient of a periodontist in private practice in New Orleans developed osteonecrosis of the jaw (ONJ), a condition that can cause severe, often irreversible and debilitating damage to the jaw, following periodontal surgical therapy. Two years prior to surgery, the patient had started receiving IV bisphosphonate therapy, or bone-sparing drugs commonly used in the treatment of osteoporosis and metastatic bone cancer to help decrease associated pain and fractures, following treatment for breast carcinoma. (2006-04-11)

Halting bone-building osteoporosis drug use cuts risk for additional atypical femur fracture in half
There is growing evidence that supports an association between atypical fractures of the femur- a rare break of the thigh bone, typically without trauma - and the use of bisphosphonates, drugs proven to enhance bone density and reduce fracture incidence caused by osteoporosis. (2012-02-08)

Popular osteoporosis drugs triple risk of bone necrosis
A University of British Columbia and Vancouver Coastal Health Research Institute study has found that a popular class of osteoporosis drugs nearly triples the risk of developing bone necrosis, a condition that can lead to disfigurement and incapacitating pain. (2008-01-15)

Drugs used to treat osteoporosis not linked with higher risk of esophageal cancer
Although some reports have suggested a link between the use of oral bisphosphonates (drugs that prevent the loss of bone mass) and esophageal cancer, analysis of medical data from more than 80,000 patients in the United Kingdom found that use of these drugs was not significantly associated with new cases of esophageal or gastric cancer, according to a study in the Aug. 11 issue of JAMA. (2010-08-10)

An extra 5 years of life an unexpected benefit of osteoporosis treatment
Australian clinical researchers have noted an extraordinary and unexpected benefit of osteoporosis treatment -- that people taking bisphosphonates are not only surviving well, better than people without osteoporosis, they appear to be gaining an extra five years of life. These findings are published in the Journal of Clinical Endocrinology and Metabolism, now online. (2011-02-02)

ASBMR responds to NEJM's study on biphosphonates
The Food and Drug Administration announced today that physicians should reassess patients with osteoporosis who are being treated with a class of drugs called bisphosphonates after three to five years of therapy to determine whether they should continue treatment. Bisphosphonates are a widely prescribed class of drugs that are proven to be effective in reducing common bone fractures in people with osteoporosis and at high risk of fractures. (2012-05-09)

Fifteen percent of osteoporosis patients who take 'drug holidays' suffer bone fractures
A Loyola Medicine study has found that 15.4 percent of patients who take so-called 'drug holidays' from osteoporosis drugs called bisphosphonates experienced bone fractures. During a six-year follow-up period, the yearly incidence of fractures ranged from 3.7 percent to 9.9 percent, with the most fractures occurring during the fourth and fifth years. (2018-05-04)

Treatment drug may cause jawbone to die
Breast cancer patients, individuals at risk for osteoporosis, and individuals undergoing certain types of bone cancer therapies often take drugs that contain bisphosphonates. Bisphosphonates may place patients at risk for developing osteonecrosis of the jaws (a rotting of the jaw bones), according to a case report and literature review that appeared in the May/June 2006 issue of General Dentistry, the Academy of General Dentistry's (AGD) clinical, peer-reviewed journal. (2006-06-12)

New materials with potential biomedical applications
New uses for bisphosphonates were discovered, as their ability to form physical gels in pure water was reported for the first time in a recent study performed in collaboration with the Universities of Jyvaskyla and Eastern Finland. (2013-11-21)

Some bisphosphonates users unfamiliar with drug's possible side effects on oral health
People undergoing bisphosphonate therapy to prevent or treat osteoporosis (a thinning of the bones) may be unfamiliar with the drug and possible adverse side effects on oral health, according to a study in the May issue of the Journal of the American Dental Association. (2010-05-26)

Bisphosphonate treatment is associated with jaw bone problems
Patients treated with intravenous bisphosphonates are at an increased risk of jaw or facial bone deterioration or infection, according to a study published online June 26 in the Journal of the National Cancer Institute. (2007-06-26)

OHSU researchers identify ocular side effects of commonly prescribed drugs
Oregon Health & Science University researchers have discovered a previously unreported side effect for a commonly prescribed osteoporosis and cancer medication. If gone untreated, the ocular side effect could cause serious vision problems. (2003-03-20)

Patients prescribed long-term corticosteroids often do not receive therapy to prevent osteoporosis
In a small study from a referral center for dermatology, most patients receiving prolonged oral corticosteroids for chronic skin diseases were not receiving therapies to prevent osteoporosis that may be caused by the drug, according to an article in the January issue of Archives of Dermatology, one of the JAMA/Archives journals. (2006-01-16)

Bone drug should be seen in a new light for its anti-cancer properties
Australian researchers have shown why calcium-binding drugs commonly used to treat people with osteoporosis, or with late-stage cancers that have spread to bone, may also benefit patients with tumours outside the skeleton, including breast cancer. (2014-11-05)

Bone loss prevention drug showing promise in advanced prostate cancer
Oral sodium clodronate may slow the development of symptomatic bone metastases and reduce the risk of death in men with advanced prostate cancer, according to a randomized controlled trial in the September 3 issue of the Journal of the National Cancer Institute. (2003-09-02)

Taking a break from osteoporosis drugs can protect bones
Taking time off from certain osteoporosis drugs may be beneficial to bone health, according to a study presented at the 2010 Annual Loyola University Health System Research Symposium. Researchers found that bone density remained stable for three years in patients who took a drug holiday from bisphosphonates, a popular class of osteoporosis drugs that can cause fractures in the thigh bones and tissue decay in the jaw bone. (2010-11-18)

Fracture risk associated with bisphosphonate drug holidays
Bisphosphonates have been shown to reduce the risk of osteoporotic fractures. To avoid possible side effects of long-term therapy, many patients take a drug holiday after several years of bisphosphonate therapy. Researchers have examined the implications of such drug holidays on fracture risk. They found that in patients who had previously suffered a vertebral fracture, a longer bisphosphonate drug holiday was associated with an increase in the risk of so-called major osteoporotic fractures. (2020-07-29)

Osteoporosis drug aids young people with cystic fibrosis not helped by standard treatments
The first randomised trial to investigate the treatment of low bone density in young people with cystic fibrosis (CF), published Online First in The Lancet Respiratory Medicine, provides compelling evidence that alendronate (a drug that curbs bone loss) is safe and can help increase bone mineral density in young patients with CF after standard treatment with calcium and vitamin D has failed. (2013-06-01)

Drug used for advanced cancer could cause exposed bone in jaw
A type of drug used to strengthen bones when cancer has spread there may be linked to a side effect that involves deterioration of the jaw bone, according to two new reviews of cancer literature. The condition, called osteonecrosis of the jaw, is marked by exposed bone in the jaw and can lead to infection, inflammation and pain. (2006-10-02)

Drugs used to fight cancer-related bone problems boost odds of jaw- or face-bone disease
Treatment with intravenous bisphosphonates -- drugs used to reduce harm done to bones by cancer or cancer therapy -- increases the risk of jaw or facial bone disease or infection, a large-scale comparative study by researchers at the University of Texas Medical Branch at Galveston has found. (2007-06-26)

Quantity vs. quality: Long-term use of bone-building osteoporosis drugs
Bisphosphonate treatments, proven to enhance bone density and reduce fracture incidence in post-menopausal women, may adversely affect bone quality and increase risk of atypical fractures of the femur when used for four or more years, according to preliminary research presented today at the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons. (2010-03-10)

The Lancet: New studies show that 2 classes of inexpensive generic drugs can reduce breast cancer deaths
Two new studies, both published in The Lancet, suggest that two different classes of drugs, aromatase inhibitors and bisphosphonates, can each improve survival prospects for postmenopausal women with early breast cancer. Moreover, the researchers suggest that the two types of drug can be used together, increasing the benefits while also decreasing some side-effects. (2015-07-23)

Women who discontinue bisphosphonates for two years or more have higher hip fracture risk
Women who took a drug holiday (temporary or permanent discontinuation of a medicine) from using bisphosphonates for more than two years have a significantly higher risk of a hip fracture compared to others who continued their treatment, according to new research findings presented this week at the 2017 ACR/ARHP Annual Meeting in San Diego. (2017-11-04)

Failure to discontinue medications can contribute to inappropriate prescribing
The continuation of drugs that are not intended to be taken indefinitely is a substantial and common problem that could contribute to over-medication, particularly in the elderly. (2018-11-12)

Osteoporosis drugs linked to reduced risk of premature death
A large cohort study has revealed a common osteoporosis drug significantly decreases premature mortality risk, likely related to a reduction in bone loss. (2019-08-12)

Women with metastatic breast cancer can safely receive bisphosphonates less frequently, without comp
Women with metastatic breast cancer to the bone may be able to receive bisphosphonates, the bone-targeting class of drugs like zoledronic acid, less often after the first year of monthly administration. With that practice change, women may also reduce their risk of serious side effects, according to a study led by researchers at The University of Texas MD Anderson Cancer Center. (2014-05-30)

Study finds one-third of women taking bisphosphonates remain at risk for fracture
A recent study of oral bisphosphonates, the most commonly prescribed osteoporosis treatment, found that approximately a third of women prescribed these drugs continue to be at elevated risk for bone fracture, an outcome that may have several origins. The retrospective cohort study was conducted under the auspices of a Regenstrief Institute-Merck collaboration. (2016-06-06)

Page 1 of 6 | 208 Results
   First   Previous   Next      Last is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to